Updated on 2 May 2012
Serum Institute of India launched a vaccine in 2009 that is administered through intranasal spray
In 2007, Dabur Pharma, one of India's leading manufacturers of anti-cancer drugs, launched Nanoxel, a novel drug delivery system for the widely used anti-cancer drug Paclitaxel. This nanoscale drug delivery system is India's first indigenously developed nanotechnology-based chemotherapeutic agent. It enables therapy to take a preferential course to the cancerous cells and directly interact with the tumor-causing agents, thereby throwing open a larger window for anti-tumor activity.
In 2008, scientists from Singapore's Institute of Materials Research and Engineering scored a breakthrough in microneedle technologies by perfecting a new range of patented microneedles that can be mass produced more readily and at a lower cost than current microneedle technologies for painless injections and extraction of bodily fluids. They had taken five years to perfect the proprietary materials technology and offer unique structures for better drug delivery.
In 2009, Serum Institute of India launched Nasovac, a vaccine for swine flu, administered through intranasal spray.
Australia-based Acrux developed a metered dose transdermal system that enables transdermal delivery of small molecule drugs without the use of skin patches. The technology is based upon absorption enhancers used for over 20 years in sunscreens. The company has applied it to treatments that are currently in clinical testing stage, including estrogen, testosterone and a pain management compound.
Australia-based Phosphagenics is leveraging on its game changing technology of drug delivery, Targeted Penetration Matrix technology, a novel delivery system that is non-invasive, non-irritant and has unique inherent properties. It has been consistently demonstrated to be able to deliver both small and large molecules through the skin and to promote absorption of the molecules.